How many investments has Deerfield Management Company made?

Deerfield Management Company has 112 tracked investments, 17 of which have exited, including 11 dated in the last 24 months.

What stage does Deerfield Management Company invest at?

Deerfield Management Company invests at the Growth, Late Stage stages.

What sectors does Deerfield Management Company focus on?

Deerfield Management Company focuses on AI & Machine Learning, Biotech, Digital Health, Healthtech, Medical Devices.

Where is Deerfield Management Company located?

Deerfield Management Company is headquartered in New York, US.

Does Deerfield Management Company lead rounds?

Deerfield Management Company has led 13 of the 24 rounds where its role is on record.

Who does Deerfield Management Company co-invest with?

Deerfield Management Company most often shares deals with HongShan Capital Group, Longwood Fund, Star51 Capital, among 3 tracked co-investors.

Deerfield Management Company

Venture capital

New York · Growth–Late Stage · 96 people tracked

Also known as DEERFIELD MANAGEMENT COMPANY, L.P.

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into Deerfield Management Company

Each arrow is one introduction. Sign up to fill in the first one.

545 people can intro you to Stephen

Ask Dan Gebremedhin to introduce you to Stephen Anastos

You →Dan · together at Massachusetts Executive Office of Health and Human Services →Stephen

465 people can intro you to Karen

Ask Jamie Chen to introduce you to Karen Heidelberger

You →Jamie · together at Deerfield Management →Karen

384 people can intro you to Konstantinos

Ask Sam Okafor to introduce you to Konstantinos Aprilakis

You →Sam · together at Private Tutor →Konstantinos

Terence Fox-Karnal327 people can intro you
David Greenwald200 people can intro you
Andrew ElBardissi99 people can intro you

Your email: who you already know at Deerfield Management Company, and who your contacts know
2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Deerfield Management Company team
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

✨ Fox Verdict

Investment thesis

Deerfield advances healthcare through the combination of investment, information, and philanthropy. It provides flexible funding models to companies spanning the healthcare ecosystem and applies AI, data, and market research to drive healthcare technology and innovation. The firm builds companies independently and alongside strategic partners, forming alliances with research institutions and technology companies. Its New York City-based not-for-profit foundation supports innovative healthcare initiatives, reflecting a broad approach that blends capital, information services, and charitable activity across the sector.

Invests inAI & Machine Learning Biotech Digital Health Healthtech Medical Devices New York New York City United States

Source: firm website, verified Sep 29, 2026.

Leave your own feedback

Stage

Growth–Late Stage

New York, NY, US

Instruments

Equity

Founded

1994

Last 12 months

4 investments

AUM

$19.1B

Tracked investments

112

Unicorns

IPOs

Acquisitions

Team · 96 people

from the firm's website & public directories

Alexis Cazé· President of the Deerfield Foundation· New York, New York

Alexis Cazé is President of the Deerfield Foundation and joined Deerfield Management in 2006, where he previously held roles including Managing Director of the Deerfield Institute, Chief Information Officer, and Chief Operating Officer. In his current role he works on expanding the Foundation's nonprofit efforts. Before Deerfield, he worked at Gerson Lehrman Group, Sanofi, and PricewaterhouseCoopers, and he holds a PharmD from the Paris University of Pharmacy and an MSc in Business from E.M. Lyon Business School.

Andrew ElBardissi· Partner· New York, New Yorkin 𝕏

A partner on Deerfield's Medical Technologies team who joined in 2017, previously a principal at Longitude Capital investing in medtech and biotech and an associate in JPMorgan's healthcare investment banking practice. He is a trained surgeon with an M.D. from the Mayo Clinic, an M.P.H. and M.B.A. from Harvard, and residency training at Harvard's Brigham and Women's Hospital and Stanford.

Brian Bizoza· Partner· New York, New Yorkin

Partner at Deerfield who joined in 2012, overseeing public fund processes and conducting research on healthcare companies. Previously a portfolio manager at S Squared Technology, an analyst at Amaranth Advisors, and an equity analyst at Lehman Brothers and Lazard Frères. Holds a B.A. from Johns Hopkins and an M.D. from SUNY Syracuse.

David Greenwald· Managing Director· New York City Metropolitan Areain

David Greenwald is a Managing Director at Deerfield Management, a healthcare investment firm focused on public and private companies, where he identifies investment opportunities and holds operational and board roles at private portfolio companies. He previously served as Director of Business Development and Corporate Partnerships at Johns Hopkins Technology Ventures and as Director of Client Solutions at Decision Resources Group, which acquired Relay Technology Management, a company he co-founded in 2008. He has lectured on entrepreneurial and corporate finance at the Johns Hopkins Carey Business School and at Tufts University, and holds a Ph.D. in Genetics from the Tufts University Sackler School of Graduate Biomedical Sciences.

Julian Harris· Operating Partner· New York, New York

Karen Heidelberger· Partner and Chief Partnerships Officer· Greenwich, Connecticut, United Statesin

Contact for partnership inquiries at Deerfield.

karenh1@deerfield.com

Konstantinos Aprilakis· Partner· New York, New Yorkin

Partner on Deerfield's Therapeutics team since 2021, focused on research and analysis of healthcare companies. Previously a biotech research analyst, including as Managing Director at Stifel, Director at Deutsche Bank, and VP at JMP Securities, and earlier a biomedical researcher. Holds a B.A. from Stony Brook and an M.D. from Weill Cornell.

Michael Hurley· Managing Director

Terence Fox-Karnal· Partner· New York, New York, United Statesin

Terence Fox-Karnal joined Deerfield in 2010 and works on the Public Structured Finance team, providing analytical and structuring services. He previously was a volatility trader at BAM Capital and a partner trading healthcare-sector equity derivatives at TORO Trading, and holds an S.B. in Finance and Economics from MIT.

Abraham Kometz· Partner· New York, New Yorkin 𝕏

Adam Greene· Partner· New York, New Yorkin

Anne Daub· Partner

Brian Chow· Managing Director

Cameron Wheeler· Partner· New York, New Yorkin

Elise Wang· Partner· New York, New Yorkin

Howard Furst· Partner· New York, New Yorkin

Jason Fuller· Partner· New York, New Yorkin 𝕏

Jim Flynn· Managing Partner· New York, New Yorkin

Jonathan Leff· Partner· New York, New York

Leslie Henshaw· Partner· Brooklyn, New Yorkin

Michael Bergen· Managing Director

Narendra Nayak· Partner· New York, New Yorkin

Nicholas Bishop· Partner· New York, New Yorkin

Nicholas Bishop is a Partner on Deerfield's Therapeutics team, which he joined in 2014, focusing on research and analysis of companies in the healthcare industry. He previously spent four years as a biotechnology research analyst at Cowen and Company and worked as a biomedical research scientist at Harvard University and MIT. He holds a B.A. with honors from Rice University and a Ph.D. from MIT, and has published scientific articles on the genetic regulation of aging and lifespan.

Peter Steelman· Partner· New York, New Yorkin

Stephen Anastos· Managing Director· New York, New Yorkin 𝕏

Sumner Anderson· Partner· New York, New Yorkin

Sumner Anderson is a Partner on Deerfield's Public Structured Finance team, which he joined in 2019 after starting at the firm in 2012 on the Therapeutics team analyzing healthcare companies. Before Deerfield, he was a pharmaceuticals research analyst at Millennium Management, a Managing Director in healthcare investment banking at Wells Fargo Securities, and a pharmaceutical analyst at Citadel Investment Group. He earned an A.B. in History and Economics from Harvard University and an M.B.A. in Finance and Accounting from New York University.

Terence Karnal· Partner· New York, New York

Timothy Leahy· Partner

Vincent Mellet· Partner· New York, New Yorkin

Katherine Lazar· Principal, Investment Strategy

Bharath Ganesan· Principal· New York, New Yorkin

Gilan Megeed· Principal· New York Cityin

Jackson Harvey· Principal· New York, New Yorkin 𝕏

Moses Adubi· Principal

Nehan Chatoor· Principal

Talia Askowitz· Principal· New York, New Yorkin

Talia Askowitz is a Principal on the Healthcare Services team at Deerfield Management, where she focuses on early and growth stage healthcare technology and services investments. She joined the firm in 2020. She earned a B.A. in Human Biology from the City University of New York's Macaulay Honors College, graduating Phi Beta Kappa and summa cum laude.

Veranika Razhkova· Principal· New York, New Yorkin 𝕏

Wenxi Chen· Principal· New York, New Yorkin

Abdul Khan· Senior Director, Biologics· Bronx, New York, United Statesin

Adriana Brito· Desktop Support Engineer

Adriana Brito joined Deerfield in 2024 as a Desktop Support Engineer. She previously worked as a Senior Help Desk Engineer consultant at GIC Private Limited and spent nearly three years at Best Buy, most recently as a Microsoft Expert. She holds a B.S. in Computer Science from New Jersey City University.

Alex Lachapelle· Director, Product and Strategy

Alexander Ashavsky· Managing Director, Data Science and Engineering· New York, New York, United Statesin

Alex Ashavsky joined Deerfield in 2018 and serves as a Managing Director on the Deerfield Intelligence team, focusing on data science and engineering. He previously held senior software engineering roles at MediaRadar and iHeartMedia, worked as a business intelligence consultant at Sky IT Group, and began his career at TransPerfect Legal Solutions.

Angela Asencio· Manager, Therapeutics Team· Harrison, New York, United Statesin

Angela Asencio joined Deerfield in 2015 and serves as a Manager on the Therapeutics Team, focusing on business operations and administration. She previously worked as an executive assistant at Barclays and AmeriFactors Financial Group, and held various roles at North Eastern Asset Recovery. She holds a B.A. in Economics from SUNY Albany.

Anthony Barsotti· Senior Director, Preclinical Pharmacology

Anthony Barsotti is a Senior Director of Preclinical Pharmacology at Deerfield Discovery and Development, joining the firm in 2020. He previously held research roles at Inzen Therapeutics, Kadmon Corporation, and Pfizer, and holds a B.A. from the University of Pennsylvania and a Ph.D. from Columbia University.

Brandon Gaitan· Director, Product & Strategy

Carly Filmanski· Executive Assistant

Executive Assistant supporting Deerfield's Medical Technologies team, joining the firm in 2025. She previously held executive and administrative roles at KBW, Viking Global Investors, Millennium Management, and other firms, and holds a B.A. in Visual and Media Arts from Emerson College.

Carolyn Cassell· Executive Assistant· United Statesin

Executive Assistant supporting the Human Resources team at Deerfield, joining in 2026. Previously an Administrative Assistant at The Raine Group and a Multi-Grade Learning Specialist at Classical Charter Schools; holds a B.S. in Psychology and Child Studies from Santa Clara University.

Christine Brideau· Vice President, Preclinical Pharmacology, Deerfield Discovery and Development

Christine Brideau joined Deerfield in 2019 and leads preclinical pharmacology within Deerfield Discovery and Development. She previously served as VP of In Vitro Pharmacology at WuXi AppTec and spent 24 years at Merck, and has co-authored over 40 peer-reviewed publications.

Christopher Freeland· Counsel, Portfolio Company Operations· New York, New York, United Statesin

Christopher Freeland joined Deerfield in 2019 as Counsel for Portfolio Company Operations, supporting the firm's External Operations team. He previously served as General Counsel and COO at Aralez Pharmaceuticals, was Associate General Counsel at AIG, and began his career as a corporate associate at Willkie Farr & Gallagher and as an investment banking analyst at Citigroup. He holds an A.B. from Princeton and a J.D. from the University of Virginia.

Christopher Jean-Pierre· Systems Engineer

Coco Dong· Director, Quantitative Applications· Yonkers, New York, United Statesin

Coco Dong, Ph.D. is a Director of Quantitative Applications on the Deerfield Intelligence team, having joined Deerfield in 2020 as a Senior Genetic Data Scientist before moving to the Intelligence team in 2023. She previously worked as a strategist at Goldman Sachs and a principal statistician at GlaxoSmithKline, and holds an M.S. in Computer Science and a Ph.D. in Biostatistics from USC.

Daniel Glass· Managing Director, Global Market Research· New York City Metropolitan Areain

Dharan Kadiyala· Associate Director, Market Research· New York City Metropolitan Areain

Edi Assis· Director, Cloud Platform Engineering

Edi Assis is a Director of Cloud Platform Engineering on Deerfield's IT team, joining in 2026. Previously held platform, cloud, and infrastructure engineering leadership roles at Soros Fund Management, Autonomy Capital Management, AQR Capital Management, and Pine River Capital Management, and holds a B.S. in Computer Information Systems from Brooklyn College.

Elizabeth Baer· Senior Associate, Investor Business Development

Elizabeth Baer joined Deerfield in 2022 as an Executive Assistant and now serves as Senior Associate for Investor Business Development. She previously worked as an administrative assistant at C & R Management Company in Salt Lake City and holds a B.S. in Business Administration from Babson College.

Elizabeth Dugan· Director, Project Management

Elizabeth Dugan, Ph.D., is a Director of Project Management on the Deerfield Discovery and Development team who joined in 2026. She previously spent over five years at PsychoGenics and over seven years at The Miami Project to Cure Paralysis, and holds a B.S. in Psychology from the University of Florida and a Ph.D. in Neuroscience from Drexel University College of Medicine.

Emily Boylan· Associate Director, Market Research

Emily Boylan is an Associate Director of Market Research on the Deerfield Intelligence team, joining the firm in 2018. She previously conducted survey research at GfK and holds a B.A. in Sociology from the University of San Francisco and an M.St. in the Study of Religion from the University of Oxford.

Emma Gigerenich· Senior Director, Applied Epidemiology

Eric Feuer· Senior Compliance Officer & Counsel· New York City Metropolitan Areain

Eric Feuer joined Deerfield in 2021 as a Senior Compliance Officer and Counsel. He previously spent seven years in compliance at Apollo Global Management and earlier worked in compliance at J.P. Morgan Chase's Corporate & Investment Bank. He holds a B.A. from Binghamton University and a J.D. from Cardozo School of Law.

Gabrielle Briganti· Communications Associate· New York, New York, United Statesin

Gabrielle Briganti is a Communications Associate who joined Deerfield in 2023 as an Executive Assistant. She previously spent over two years at SL Green Realty Corp., most recently as Executive Assistant to the COO, and holds a B.S. in Business Administration from the University of Richmond.

Gopal Kotecha· Director, Quantitative Research

Harold Davidson· Senior Transactions Counsel

Harold Davidson joined Deerfield in 2025 as Senior Transactions Counsel, working in business operations, legal, and compliance. He previously was a Corporate Partner at Katten Muchin Rosenman for over two years and a Partner at McDermott Will & Emery for over 15 years. He holds a B.A. in Political Science from Emory University and a J.D. from NYU School of Law.

Helena Howard· Compliance Associate· New York City Metropolitan Areain

Hsueh-Cheng Huang· Senior Director, Preclinical Pharmacology

Jared Anderman· Managing Director, Data Analytics· New York, New York, United Statesin

Jared Anderman is a Managing Director, Data Analytics on the Deerfield Intelligence team, joining the firm in 2010. He previously worked as a compensation analyst at Bloomberg LP/Geller & Co. and Cantor Fitzgerald, and began his career at JPMorgan Chase; he holds a B.S. in Marketing from the University of Delaware.

Jennifer Hsieh· Director, Compliance· New York, New York, United Statesin

Jessica Sagers· Communications Inquiries contact· Washington DC-Baltimore Areain

Contact for communications inquiries at Deerfield.

jsagers@deerfield.com

Jinho Jang· Director, Quantitative Research· New York, New York, United Statesin

Jonathan Isler· Partner and Chief Financial Officer, Funds· New York, New York, United Statesin

Karen Arnone· Chief Property and Development Officer

Karen Arnone joined Deerfield in 2005 and serves as Chief Property and Development Officer, overseeing the development and operations of the firm's healthcare innovation center at 345 Park Avenue South. She previously served as Deerfield's Chief Administrative Officer and led its HR function, and earlier held administrative roles at Balyasny Asset Management and XL Reinsurance.

Kevin Goncalves· Senior Director, Preclinical Pharmacology

Maria Guglielmo· Manager, Recruiting and Employee Experience· Yonkers, New York, United Statesin

Marissa Carnevale· Director of Talent Acquisition, Portfolio Company Operations

Carnevale joined Deerfield in 2018 and works on the External Operations team focusing on talent acquisition for portfolio companies. She previously held talent and recruiting roles at Johnson & Johnson, Bristol-Myers Squibb, The Judge Group, Taratec Development Corporation, SRG Woolf Group, and Kelly Scientific Resources, and holds a B.S. in Biology from Binghamton University.

Mellissa Gray· Senior Scientist, Protein Sciences· New York, New York, United Statesin

Michael Cingolani· Associate Director, Cybersecurity

Cybersecurity associate director who joined Deerfield in 2022, previously an Information Security Analyst at Disney Streaming Services for four years and earlier a security operations analyst at BASF. Holds a B.S. in Business and Information Systems from New Jersey Institute of Technology.

Michael Farrell· Head of Portfolio Company Operations· New York City Metropolitan Areain

Michael Farrell leads Portfolio Company Operations on Deerfield's External Operations team, joining in 2016 as an Operations Executive overseeing investments in the firm's Private Design and Healthcare Innovations Funds. He previously held senior finance roles including VP of Finance at Amarin Corporation and controller/accounting positions at several pharmaceutical companies, and began his career at Arthur Andersen as a CPA.

Nicholas Dow· Director, Software Engineering· Mumbai Metropolitan Region

Nicholas Dow is a Director of Software Engineering on the Deerfield Intelligence team, having joined the firm in 2026. He previously worked as a Machine Learning Engineer at Delta Global Management and began his career as a Quant Developer at Wells Fargo Securities, and holds a B.A. in Statistics and Computer Science from Harvard College.

Nicolas Jbeyli· Head of Strategy and Operations

Nicole Layton· Senior Associate, Investor Relationship Management· New York City Metropolitan Areain

Oleg Laptenko· Principal Scientist, Preclinical Pharmacology· Bronx, New York, United Statesin

Pooja Deo· Senior Director, Business Intelligence· New York, New York, United Statesin

Senior Director on the Deerfield Intelligence team, joined the firm in 2021. Previously worked in business intelligence and data analyst roles at Guidepoint, Outcome Health, New Jersey Parent Caucus, and L&T InfoTech in India. Holds a B.E. in Computer Science from the University of Pune and an M.S. in Information Systems from Stevens Institute of Technology.

Raheleh Hatami· Senior Director, Portfolio Strategy and Innovation

Roberto Herrera· Associate Director, Solutions and Support Manager· Middletown, New York, United Statesin

Rodrigo Ceballos· Director, AI Engineering

Director of AI Engineering on the Deerfield Intelligence team who joined in 2025. Previously spent three years at Georgian (most recently AI Tech Lead) and worked at Paige AI as a Senior AI Engineer; holds a B.S. from NYU Abu Dhabi and an M.S. in Neural Systems and Computation from ETH Zurich.

Sabrina Khanum· Desktop Support Engineer

Sam Galindo· Director, Innovation Alliances

Scott Donohue· Senior Director, Market Access· New York City Metropolitan Areain

Scott Donohue is a Senior Director, Market Access on the Deerfield Intelligence team, joining in 2023. He previously held roles at IQVIA, TG Therapeutics, and Bristol Myers Squibb in the healthcare industry. He holds a B.A. from Colgate University and an M.P.A. in Health Policy and Management from New York University.

Susanna Hall· Senior Director of Data Integrity and Operations

Susannah Barbee· Vice President, Translational Immunology· New York, New York, United Statesin

Vice President of Translational Immunology within Deerfield Discovery and Development, having joined Deerfield in 2024. She previously held translational biology and immuno-oncology research leadership roles at TRex Bio, Five Prime Therapeutics, and Amplimmune, and holds an A.B. from Harvard and a Ph.D. in Biology from Caltech.

Tatsuya Kano· Senior Project Manager, IT

Victoria Gaddy· VP, Portfolio Company Operations HR & Strategy

Nicholas Lane· Director

Peter Young· Director

Alison Stamas· Associate· New York, New Yorkin

Crystal Wright· Associate· New York, New Yorkin

Eddie Yang· Analyst· New York, New Yorkin

What they invest in

from 89 of 112 portfolio companies

Healthtech ×52Biotech ×48Medical Devices ×23Digital Health ×21AI & Machine Learning ×19SaaS ×8Deep Tech ×7Enterprise Software ×5

HQs:United States×82Chile×1United Kingdom×1Israel×1Philippines×1

Investments · 112 tracked

founders shown can be your intro path

By year:2026 · 3 2025 · 7 2024 · 9 2023 · 4 2022 · 15 2021 · 9 2020 · 13 2019 · 4 2018 · 9 2017 · 4 2016 · 4 2015 · 695 dated

Biomxbiomx.com in 𝕏NYSE: PHGEMar 2024 · $50M

BiomX builds a portfolio of defense and security companies through subsidiaries, partnerships, and acquisitions, focusing on detection systems, aerial technologies, and infrastructure security.

AI & Machine LearningBiotechCybersecurityDeep TechDefense TechHardwareNess Ziona

Jonathan Solomon(Chief Executive Officer)inMerav Bassan(Chief Development Officer)in Marina Wolfson(Chief Financial Officer)inJesse Goodman(Director)Alan Moses(Director)Jonathan Leff(Director)

Co-investorsAMR Action Fund Baruch Future Ventures NSG Ventures OrbiMed SBI JI Innovation Advisory Ltd.Seventure Partners +2 more

Black Diamond Therapeutics, Incblackdiamondtherapeutics.comNASDAQ: BDTX

Black Diamond Therapeutics develops small-molecule kinase inhibitors targeting families of oncogenic mutations across cancer types, including its lead candidate silevertinib for EGFR-mutant lung cancer and glioblastoma.

Elizabeth Buck(Chief Scientific Officer)inBrent Hatzis-Schoch(Chief Operating Officer and General Counsel)inSergey Yurasov(Chief Medical Officer)inMelanie Morrison(Chief Development Officer)

Co-investorsLAV Lilly Asia Ventures New Enterprise Associates (NEA)Nextech Invest NSG Ventures RA Capital +4 more

Cabaletta Biocabalettabio.com in 𝕏NASDAQ: CABA

Cabaletta Bio is a clinical-stage biotechnology company developing engineered T cell therapies for patients with autoimmune diseases.

BiotechHealthtechRadnor, US

Steven Nichtberger(Executive Officer, Director)in Steven Nichtberger, MD(Founder)inDan Geffken(Executive Officer)inAnup Marda(Chief Financial Officer)inMark Simon(Director)

Board Brian Daniels(Director)in

Co-investors5AM Ventures Bain Capital Life Sciences

Edgewise Therapeuticsedgewisetx.com in 𝕏NASDAQ: EWTX

Edgewise Therapeutics discovers and develops small molecule medicines targeting muscle proteins to treat neuromuscular and cardiac diseases, including sevasemten for muscular dystrophies and EDG-7500 for cardiomyopathy, leveraging a proprietary drug discovery platform based on muscle physiology and high-throughput functional assays.

BiotechDigital HealthBoulder, US

Kevin Koch(Executive Officer, Director)in Alan Russell(Director)in Badreddin Edris(Director and Co-Founder)in Kenneth Harrison(Director)

Board Peter Thompson(Director)inJonathan Root(Director)in

Co-investorsBoulder Ventures Foresite Capital OrbiMed US Venture Partners Viking Global Wellington Management +1 more

Editas Medicineeditasmedicine.com in 𝕏NASDAQ: EDITAug 2015

Editas Medicine develops gene editing medicines using CRISPR/Cas9 and CRISPR/Cas12a technology to treat serious diseases including blood disorders, cardiovascular conditions, and cancer.

BiotechDeep TechMedical DevicesCambridge, US

Feng Zhang(Scientific Founder, Core Member, Broad Institute of MIT and Harvard)in George Church(Scientific Founder, Professor of Genetics, Harvard University and MIT)inKeith Joung(Scientific Founder, Professor of Pathology, Harvard Medical School)in David Liu(Scientific Founder, Professor of Chemistry and Chemical Biology, Harvard University)inKatrine Bosley(Executive Officer, Director)inVic Myer(Executive Officer)in

Co-investorsEcoR1 Capital GV (Google Ventures)Sofinnova Ventures Viking Global Atlas Venture Flagship Ventures +1 more

Foghorn Therapeuticsfoghorntx.comNASDAQ: FHTXMay 2024

Foghorn Therapeutics is a clinical-stage biotech developing chromatin-targeted cancer drugs via its Gene Traffic Control platform, including a candidate co-developed with Eli Lilly.

Adrian Gottschalk(President and Chief Executive Officer)

Co-investorsFlagship Pioneering Xeraya Capital Biotechnology Value Fund

Genedxgenedx.com in 𝕏NASDAQ: WGSSeries C · Jul 2020 · $120M

GeneDx provides advanced genetic testing and clinical interpretation services to help clinicians diagnose rare and inherited genetic disorders, with AI-driven genomic intelligence that supports patient care decisions and accelerates research and drug discovery.

AI & Machine LearningBiotechDigital HealthHealthtech

Katherine Stueland(CEO)in

Co-investorsOak HC/FT

Kiniksakiniksa.com in 𝕏NASDAQ: KNSA

Kiniksa is a global biopharmaceutical company that discovers and develops novel therapies for patients with unmet medical needs, with a focus on cardiovascular diseases and related conditions.

BiotechMedical DevicesHamilton

THOMAS W BEETHAM(Executive Officer)inSanj K. Patel(Chief Executive Officer and Chairman of the Board)

BoardSTEPHEN R BIGGAR(Director)FELIX J BAKER(Director)G. BRADLY COLE(Director)RICHARD S LEVY(Director)

Co-investorsSofinnova Ventures Sofinnova Venture Partners

Mirum Pharmaceuticalsmirumpharma.com in 𝕏NASDAQ: MIRMSeries A · Nov 2018 · $120M

Mirum Pharmaceuticals is a biopharmaceutical company that develops and delivers therapies for people living with rare diseases.

BiotechHealthtechSan Diego, US

Chris Peetz(Co-founder & Chief Executive Officer)in Eric Bjerkholt(Executive Officer)in Peter Radovich(Executive Officer)in

Board Patrick Heron(Director)inMichael Grey(Director)Timothy Walbert(Director)

Co-investorsChiesi Ventures Frazier Life Sciences Longitude Capital MESA VERDE VENTURE PARTNERS New Enterprise Associates (NEA)Pappas Capital +4 more

Pacific Biosciences of Californiapacificbiosciences.com in 𝕏NASDAQ: PACB

Pacific Biosciences develops long-read DNA and RNA sequencing platforms and kits for genomics research, including whole genome, targeted, epigenetic, and RNA sequencing applications.

BiotechDeep TechMedical DevicesMenlo Park, US

Christian O. Henry(Executive Officer, Director)inJeff Eidel(Executive Officer)in Susan G. Kim(Executive Officer)inMark Van Oene(Executive Officer)

BoardWilliam W. Ericson(Director)Hannah A. Valantine(Director)

Co-investorsDag Ventures Kleiner Perkins Maverick Capital Mohr Davidow Ventures The Blackstone Group

Scynexisscynexis.com in 𝕏NASDAQ: SCYX

SCYNEXIS develops fungerp-based antifungal therapies, including SCY-247, for treating and preventing severe, progressive, and often fatal fungal diseases and antimicrobial-resistant infections.

BiotechDurham, US

Yves J. Ribeill(Executive Officer, Director)inCharles F. Osborne, Jr.(Executive Officer)Brian Schwab(Executive Officer)in David Angulo(Chief Executive Officer, President and Director)in

BoardLaurent Arthaud(Director)Mounia Chaoui(Director)

Co-investorsDecheng Capital Foresite Capital RA Capital

Xilio Therapeuticsxiliotx.com inNASDAQ: XLO

Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment.

BiotechHealthtechWaltham, US

René Russo(Executive Officer, Director)inJoseph Farmer(Executive Officer)Timothy Clackson(Executive Officer)Christopher Frankenfield(Chief Financial and Operating Officer)in Katarina Luptakova(Chief Medical Officer)inPaul Clancy(Director)

Co-investorsBain Capital Life Sciences Bay City Capital F-Prime Capital M Ventures MRL Ventures Fund RA Capital +9 more

Medical Micro Instrumentsmmimicro.com in 𝕏Mar 2024✓ verified

MMI develops miniaturized robotic surgical instruments and platforms to enable surgeons to perform complex microsurgery and supermicrosurgery on delicate anatomical structures with greater precision.

HealthtechMedical DevicesRoboticsJacksonville, US

Mark Toland(Executive Officer, Director)inAndrew Cleeland(Director)Justin Lynch(Director)inTheresa Jean Cameron(Director)Caleb Moore(Executive Officer)Augusto Vianna Castello(Director)

Board seat Andrew ElBardissi· per SEC Form D

Co-investorsAndera Partners BioStar Capital Fidelity Investments RA Capital Corewell Health Ventures Fountain Healthcare Partners

NXT Biomedicalnxtbiomedical.comMay 2021✓ verified

NXT Biomedical is a medical device incubator that develops and spins out startups building clinical medical technologies aimed at addressing unmet needs and reducing healthcare costs.

BiotechHealthtechMedical DevicesIrvine, US

Stanton Rowe(CEO)inDon Bobo(Director)

BoardKadhiresan V Kadir(Director)Steven Hochberg(Director)Andrew Cleeland(Director)

Board seat Andrew ElBardissi· per SEC Form D

Aloalosolutions.com in✓ verified

Alo Solutions provides capital investment and practice transition support services for independent physicians seeking to expand their practices, plan for succession, or transition their patient panels.

Digital HealthEnterprise SoftwareFintechHealthtechSaaSRaleigh, US

Matt Eirich(CEO)in Angie Cain(Chief Administrative Officer)inLynn Gordon(Chief Legal & Compliance Officer)in

Pleno Inc.plenoinc.com in✓ verified

Pleno develops a genomic testing instrument platform designed to make multiomics testing faster, lower-cost, and higher-plex than existing methods like NGS, PCR, and microarrays.

BiotechHardwareHealthtech

Co-investorsForesite Capital Medical Excellence Capital

Spectrawavespectrawave.com in 𝕏May 2019✓ verified

SpectraWAVE develops optical and computational imaging technologies to diagnose and guide treatment decisions for patients with coronary artery disease and cardiovascular disease.

AI & Machine LearningDeep TechHealthtechMedical DevicesBedford, US

Eman Namati(President & CEO)inGuillermo Tearney(Founder; Professor of Pathology, Massachusetts General Hospital)Gregg Stone(Founder; Professor of Medicine, Mount Sinai Heart Health System)James Muller(Founder; Cardiologist, Brigham and Women's Hospital)inJeffrey O'Donnell(Founder; Managing General Partner, Runway Healthcare)Vivek Walimbe(Chief Operating Officer)in

Co-investorsLumira Ventures S3 Ventures SV Health Investors Johnson & Johnson Innovation – JJDC

Acutus Medicalacutusmedical.comJul 2022

HealthtechCarlsbad, US

Christoph Scharf(Director)inRandy Werneth(Executive Officer, Director)Graydon Beatty(Executive Officer)inVince Burgess(Director)inJohn Dahldorf(Executive Officer)

BoardAditya Puri(Director)

Board seat Andrew ElBardissi· per SEC Form D

Co-investorsAdvent Life Sciences OrbiMed Xeraya Capital Formation Group GE Ventures Index Ventures

Adelaadelabio.com in 𝕏Jul 2025

Adela develops blood-based tests for cancer detection using epigenetics and liquid biopsy technology, aimed at helping patients and clinicians detect and act on cancer earlier.

BiotechDigital HealthHealthtechMedical DevicesFoster City, US

Daniel Diniz De Carvalho(Executive Officer, Promoter)Scott Bratman(Executive Officer, Director)in Anne-Renee Hartman(Founder)inAlan Williams(Executive Officer)in Lisa Alderson(Executive Officer, Director)inPriscilla Huang(Executive Officer)in

Board seat Andrew ElBardissi· per SEC Form D

Co-investorsDecheng Capital F-Prime Capital OrbiMed Menlo Ventures

Appello Pharmaceuticalsappellopharma.comJan 2022SEC filingmedium confidence

Appello Pharma is a biopharmaceutical company focused on drug discovery and development for neurological and metabolic diseases.

BiotechDigital HealthHealthtechMedical DevicesNashville, US

Dr. Laden(Co-founder)Christopher Rand(Executive Officer)Vaughn Bryson(Director)Jeff P. Conn(Director)

BoardWilliam Slattery(Director)Howie Furst(Director)in

Board seat Howard Furst· per SEC Form D · $13.5M raise · filed Jan 2022

Co-investorsMountain Group Capital Relevance Ventures

Audentes Therapeuticsastellasgenetherapies.com inSeries B · Aug 2015 · $43M

BiotechSan Francisco, US

Matthew Patterson(Executive Officer, Director)in

Board Jonathan Silverstein(Director)inSteve Squinto(Director)in Kush Parmar(Director)inThomas Woiwode(Director)

Board seat Jonathan Leff· per SEC Form D

Co-investorsAsset Management Company RA Capital venBio Partners 5AM Ventures OrbiMed Venrock

Aurion Biotechaurionbiotech.com inApr 2022 · $120M

Aurion Biotech develops regenerative cell therapies for ophthalmology, focused on treating blindness and vision loss from corneal endothelial disease.

BiotechHealthtechMedical DevicesSeattle, US

DAVID ROSTOV(Executive Officer)inGREG KUNST(Executive Officer, Director)PATRICK LALLY(Director)JEANNETTE BANKES(Director)CHRISTINE MCCAULEY(Director)ARNAUD LACOSTE(Executive Officer)

Board seat Andrew ElBardissi· per SEC Form D

Co-investorsVisionary Ventures Flying L Partners

Axon Therapiesaxontherapies.comJan 2019SEC filingmedium confidence

Axon Therapies develops the SAVM procedure, an implant-free catheter-based ablation therapy that targets the right greater splanchnic nerve to reduce overactive sympathetic nerve activity in patients with heart failure with preserved ejection fraction (HFpEF).

HealthtechMedical DevicesNew York, US

Howard R. Levin(Executive Officer, Director)Mark Gelfand(Executive Officer)

Board Paul LaViolette(Director)in

Board seat Andrew ElBardissi· per SEC Form D · $15M raise · filed Feb 2019

Co-investorsStar51 Capital Action Potential Venture Capital Ltd.Earlybird Venture Capital SV Health Investors

Dracen Pharmaceuticalsdracenpharma.comSeries A · Jan 2018 · $40M

Dracen Pharmaceuticals is a private drug developer working at the intersection of cancer metabolism and immuno-oncology, developing glutamine antagonists that inhibit tumor glutamine metabolism and remodel the tumor microenvironment.

BiotechHealthtechBaltimore, US

Robert Wild(Co-founder & Chief Scientific Officer)Thomas M. Estok(Chief Executive Officer, President and Treasurer)Drew Pardoll, M.D., Ph.D.(Director)

BoardRobert Jackson(Director)

Board seat Jonathan Leff· per SEC Form D

Co-investorsBiotech Investments S.R.O i&i Biotech Fund OUP (Osage University Partners)Sofinnova Ventures

Element Scienceelementscience.com inMar 2020SEC filingmedium confidence

Element Science is a medical technology company that develops the Jewel, an FDA-approved adhesive-based wearable cardioverter defibrillator designed to protect patients at risk of sudden cardiac arrest.

AI & Machine LearningDigital HealthHardwareHealthtechMedical DevicesSan Francisco, US

Uday N. Kumar(Executive Officer, Director)in Uday Kumar(Founder)in

BoardRussell Hirsch(Director)Neil Exter(Director)in Krishna Yeshwant(Director)inWilliam H. Kucheman(Director)

Board seat Andrew ElBardissi· per SEC Form D · $145.6M raise · filed Mar 2020

Co-investorsGV (Google Ventures)Third Rock Ventures

Elion Therapeuticseliontx.com inSeries B · Jun 2024 · $81M

Clinical-stage biotech developing next-generation polyene antifungals for life-threatening invasive fungal infections.

BiotechNew York, US

Kieren Marr(Executive Officer, Director)

BoardJim Flynn(Director)Martin Heidecker(Director)in

Board seat Jonathan Leff· per SEC Form D

Co-investorsAMR Action Fund Illinois Ventures

InCarda Therapeuticsincardatherapeutics.com inOct 2020 · $30M

Incardatherapeutics develops drug therapies for treating atrial fibrillation using synergistic combinations of anti-arrhythmic agents, with delivery platforms designed for both hospital and at-home settings.

BiotechDigital HealthMedical DevicesBrisbane, US

Carlos A. Schuler(Executive Officer, Director)in John S. Patton(Executive Officer, Director)inRangachari Narasimhan(Executive Officer, Director)Grace Colon(Executive Officer, Director)inMiller Samantha(Executive Officer)

BoardMcCarthy Reenie(Director)

Board seat Andrew ElBardissi· per SEC Form D

Co-investorsAsset Management Company HealthCap Sofinnova Ventures

Innervace inAug 2022 · $40M

BiotechNew York, US

Nader Halim(Executive Officer, Director)Althea Stillman(Executive Officer, Director)

Board David Greenwald(Director)in

Board seat Jonathan Leff· per SEC Form D

Co-investorsBioAdvance

Neochordneochord.com in 𝕏Nov 2022

NeoChord develops a medical device system for beating heart mitral valve repair in patients with mitral valve regurgitation.

Advanced ManufacturingHealthtechMedical DevicesMaple Grove, US

Todd Berg(Executive Officer, Director)inDavid H. Chung(Executive Officer, Director)inRon Nelson(Executive Officer)in

Board Casey Tansey(Director)Mudit K. Jain(Director)

Board seat Andrew ElBardissi· per SEC Form D

Co-investorsBaird Capital Treo Ventures, Llc US Venture Partners U.S. Venture Partners

Reprieve Cardiovascularreprievecardio.comAug 2020

Reprieve Cardiovascular develops a decongestion management system that uses real-time patient data to guide and personalize diuretic therapy for fluid removal in heart failure patients.

Digital HealthHealthtechMedical DevicesMilford, US

Tony Fields(Executive Officer)Adam Bartnik(Executive Officer)inMark Pacyna(Executive Officer, Director)inJim Dillon(Executive Officer, Director)Hanson S. Gifford III(Director)Gregory W Mann(Executive Officer)

Board seat Andrew ElBardissi· per SEC Form D

Co-investorsArboretum Ventures Lightstone Ventures Rex Health Ventures Genesis Venture Capital Sante Ventures

About Neomorphneomorph.com in 𝕏

Neomorph develops a molecular glue discovery platform to identify small-molecule medicines that degrade disease-causing proteins through targeted protein degradation.

AI & Machine LearningBiotechDeep TechSan Diego, US

Co-investorsLongwood Fund

Actio Biosciencesactiobio.com in 𝕏Series A · Sep 2023 · $55M

Actio is a precision medicine company developing therapeutics by leveraging genetic insights to treat rare diseases and common conditions at their molecular root.

AI & Machine LearningBiotech

Co-investorsDroia Ventures Canaan Partners

Adaptive Phage Therapeuticsaphage.com in 𝕏Series B · May 2021 · $41M

Aphage develops AI and sensor technologies to identify, track, and classify physical threats across borders, infrastructure, and transportation networks for government and security organizations.

AI & Machine LearningBiotechDefense TechGovTechGaithersburg, IL

Gregory L. Merril(Executive Officer, Director, Promoter)Carl R. Merril(Executive Officer, Director)in

Board Jonathan Leff(Director)inEvan Loh(Director)Jana Jensen(Director)Raymond L. Martz(Director)

Co-investorsHackensack Meridian Health Bear's Den Maryland TEDCO TEDCO AMR Action Fund Sofinnova Ventures

Annexonannexonbio.com in 𝕏Jul 2020 · $100M

Annexon Bio develops early complement inhibitors that target C1q, the initiating molecule of the classical complement pathway, to treat autoimmune, neurodegenerative, and ophthalmic diseases.

BiotechHealthtechSo. San Francisco, US

Ben Barres(Scientific Co-Founder)Douglas Love(Founder)inMark L Smith(Executive Officer)Campbell Murray(Director)inThomas Wiggans(Director)Ricky Sun(Director)

Co-investorsBain Capital Life Sciences Correlation Ventures New Enterprise Associates (NEA)BlackRock Blackstone Life Sciences Clarus Ventures +2 more

Ascertainascertain.comSeries A · Apr 2025 · $10M

Ascertain provides an agentic AI platform that automates healthcare administrative work such as prior authorizations, referrals, eligibility checks, and care coordination by integrating with existing systems and embedding human review.

AI & Machine LearningDigital HealthHealthtechNew York, US

Mark Michalski(Executive Officer, Director)inMarc Berger(Executive Officer)Gregg Fergus(Executive Officer, Director)Laurence Kraemer(Executive Officer)

BoardMoses Adubi(Director)Konstantine Costalas(Director)

Co-investorsAegis Ventures

Cohere Healthcoherehealth.com inFeb 2024 · $50M

Cohere Health provides a platform aimed at aligning the interests of patients, physicians, and health plans to support care decisions and improve member outcomes.

AI & Machine LearningDigital HealthEnterprise SoftwareHealthtechSaaSBoston, US

Siva Namasivayam(Executive Officer, Director)inRobert Shepardson(Executive Officer)in Kristen Carucci(Executive Officer)inDuncan Reese(Executive Officer)

BoardDavid Barrett(Director)Amir Debourou(Director)

Co-investorsCota Capital Flare Capital Partners Longitude Capital Define Ventures Flare Capital Strategies Polaris Partners +1 more

ConcertoCareconcertocare.com in 𝕏Feb 2022 · $105M

ConcertoCare provides coordinated in-home and center-based medical, behavioral, and social care for seniors and adults with complex care needs who have Medicare, Medicare Advantage, or Medicare+Medicaid coverage.

Digital HealthHealthtechLongevity

Co-investorsAtento Capital Obvious Ventures SteelSky Ventures Addepar Arboretum Ventures Vast Ventures +1 more

Corticacorticacare.com inApr 2023 · $75M

Cortica provides in-home, in-clinic, and telehealth neurological therapies for children with autism and developmental differences, integrating neurological, biomedical, behavioral, speech-language, and sensorimotor treatments.

Digital HealthHealthtechMedical DevicesSan Diego, US

Dr. Suzanne Goh(Founder)Neil Hattangadi(Executive Officer, Director)inBriana Elvaiah(Executive Officer)in

Board Ryan Drant(Director)inStephen Anastos(Director)Justin Brock(Director)in

Co-investors.406 Ventures AIF APERTURE Venture Partners CVS Health Ventures Echo Health Ventures Longitude Capital +5 more

cystetic Medicinescysteticmedicines.comNov 2020

cystetic Medicines is a drug development company creating an inhaled dry-powder therapy based on an FDA-approved antifungal compound to treat cystic fibrosis, targeting the roughly 10% of patients not helped by existing modulators.

BiotechHealthtechMedical DevicesChampaign, US

MARTIN BURKE, MD., PH.D.(Director)Dr. Martin D. Burke(Co-founder)Dr. Michael J. Welsh(Co-founder)Dr. Jeffry Weers(Chief Technology Officer)PETER W STEELMAN(Director)inJONATHAN RAMOS(Director)

Co-investorsIllinois Ventures

Deerfield Catalystdfcatalyst.com in

Deerfield Catalyst is a medtech incubator that develops medical technology solutions aimed at improving patient outcomes and care delivery.

HealthtechMedical Devices

Howard Levin(CEO & CMO)in Mark Gelfand(Chief Technology Officer)in Zoar Engelman(Chief Science Officer)in Adam Rosenwach(Chief Business Officer)inMaybelle Jordan(Chief Strategy Officer)in

Co-investorsStar51 Capital

ElevenLabselevenlabs.io in 𝕏Series B · Jan 2024 · $80M

ElevenLabs is an AI research and product company that builds voice generation and audio processing platforms for creating human-like voice interactions with technology.

AI & Machine LearningCreator EconomyEnterprise SoftwareSaaSLondon, GB

Mati Staniszewski(Founder & CEO)in Piotr Dabkowski(Co-founder)inHannah C(Founder)Mateusz Jakub Staniszewski(Co-founder)in

Board Jennifer Li(Director)in

Co-investorsAir Street Capital Alkeon Innovation Andreessen Horowitz Anti Aspire11 Bond Capital Management +42 more

Eligibleeligible.comSeed · Jan 2015

Eligible provides APIs that healthcare businesses use to manage insurance billing and claims processing.

Developer ToolsHealthtechNew York City, US

Katelyn Gleason(Founder/CEO)

Co-investorsJames Beshara Fund Y Combinator Andreessen Horowitz Anvil Capital Athena Advisors General Catalyst +3 more

Encodiaencodia.comSeries C · Jan 2021 · $75MDefunct

San Diego protein-sequencing company behind the ProteoCode platform; ceased operations in late 2025.

Co-investorsARCH Venture Partners Decheng Capital Alexandria GV (Google Ventures)Nan Fung Life Sciences Northpond Ventures

Excelsior Sciencesexcelsiorsci.com inSeries A · Dec 2025 · $95M

Excelsior Sciences develops automated chemistry technology for small-molecule discovery and manufacturing, targeting pharmaceutical and materials development.

AI & Machine LearningBiotechDeep Tech

Marty BurkeBartosz Grzybowski Michael Foley(CEO)in Jana Jensen(COO)in

Co-investorsKhosla Ventures Sofinnova Partners Cornucopian Capital Management Illinois Ventures

Frontier Medicinesfrontiermeds.com in 𝕏Aug 2025 · $80M

Frontier is a drug discovery company developing small-molecule covalent drugs aimed at previously undruggable protein targets across the proteome.

AI & Machine LearningBiotechSouth San Francisco, US

Chris Varma, Ph.D.(Executive Officer, Director)Chris Varma(Co-founder, Chairman and CEO)inJim Winkler(Executive Officer)Johannes Hermann, Ph.D.(Executive Officer)Kevin Webster(Executive Officer)inGregory Chow(Executive Officer)

Co-investorsBerkeley Catalyst DCVC (Data Collective)Droia Ventures Felicis Ventures MPM BioImpact RA Capital +1 more

Generation Biogenerationbio.comFeb 2018 · $100M

BiotechCambridge, US

Geoff McDonoughy(Executive Officer, Director)Glenn Goddard(Executive Officer)Mark Angelino(Executive Officer)

Board Jason Rhodes(Director)in Catherine Stehman-Breen(Director)Anthony Quinn(Director)

Co-investorsAtlas Venture Foresite Capital Wellington Management Casdin Capital F-Prime Capital Fidelity Investments +1 more

Halluxhalluxinc.com inDec 2015

Hallux Inc. develops Hallux Subungual Gel (HSG), a physician-administered terbinafine treatment applied directly to the nail bed to treat onychomycosis (fungal nail infection).

BiotechHealthtechMedical DevicesLaguna Hills, US

Hendrik Arend Kroon(Executive Officer)Mark Taylor(Executive Officer, Director)inJay Birnbaum(Executive Officer, Director)

Board Peter Steelman(Director)inZheng Su(Director)Bryan Sendrowski(Director)

Homology Medicineshomologymedicines.com inSeries A · Jul 2017 · $44M

Clinical-stage genetic medicines company using human-derived AAV vectors and nuclease-free gene editing for rare diseases.

BiotechBedford, US

Siyamak Rasty(Executive Officer)Albert Seymour(Executive Officer)

BoardSteven Gillis(Director)Arthur Tzianabos(Executive Officer, Director)Kush Parmar(Director)inRichard Gregory(Director)

Co-investors5AM Ventures ARCH Venture Partners OUP (Osage University Partners)Alexandria Fidelity Investments HBM Healthcare Investments +5 more

Humanityhumanity.health in 𝕏Jul 2022 · $6M

Humanity offers an enterprise employee wellness platform that uses biological age monitoring to help teams improve health and productivity.

Digital HealthHealthtechHR TechLongevityWellness & Fitness

Peter Ward(Founder)in

Co-investorsOne Way Ventures Scientia Ventures TrueSight Ventures Andreessen Horowitz Jump Crypto Jumpstart Nova +2 more

Humanityhumanity.com inMar 2020

Humanity provides AI-powered employee scheduling and shift-planning software for frontline and enterprise workforces, automating schedule building, demand forecasting, and labor-cost control.

Future of WorkHR TechSaaSBoston, US

Peter Ward(Executive Officer, Director)inMichael Geer(Director)

Co-investorsPoint Nine SaaS Capital Team Builder Ventures Jumpstart Nova

interleukininterleukin.co in 𝕏

Interleukin operates a B2B platform for sourcing and procuring medical products and services, letting registered buyers discover accredited suppliers, request quotes, send purchase orders, and pay on terms in one system.

B2B MarketplacesHealthtechMedical Devices

Co-investorsBuko Ventures Janus Henderson Investors

IntusCareintuscare.comSeries A · Nov 2022 · $14M

IntusCare builds a technology ecosystem for PACE (Programs of All-Inclusive Care for the Elderly) organizations, offering population health, utilization management, and risk adjustment tools to support care delivery, financial performance, and regulatory compliance.

AI & Machine LearningDigital HealthHealthtechProvidence, US

John Robert Felton(Executive Officer, Director)Robbie Felton(Founder)inEvan Jackson(Founder)in Alex Rothberg(Founder)in

Board William Helman(Director)inGilbert Addo(Director)

Co-investorsEqual Opportunity Ventures Green Egg Ventures Jumpstart Nova Service Provider Capital Westbound Equity Partners Collab Capital +1 more

Jaguar Gene Therapyjaguargenetherapy.com inSeries A · Apr 2021 · $139M

Jaguar Gene Therapy develops gene therapy treatments for severe genetic diseases, focusing on AAV-based platform therapies designed to deliver one-time, long-lasting treatments.

BiotechHealthtechMedical DevicesLake Forest, US

Joseph Nolan inJoe Nolan, MBA(Chief Executive Officer)

Co-investorsAIF ARCH Venture Partners JDRF T1D Fund Goldman Sachs Samsung Ventures

Larkgetlark.ai in 𝕏Oct 2021

Lark provides AI-powered testing infrastructure for engineering teams that can test UIs, APIs, SDKs, and async workflows through natural language tests.

AI & Machine LearningDeveloper ToolsEnterprise SoftwareSan Francisco, US

Vijit Dhingra(Founder)in Jack Brown(Founder)in

Co-investorsY Combinator SteelSky Ventures Applied Angels Arbor Ventures Bridge Bank Franklin Templeton +3 more

Larktrylark.ai inOct 2021 · $100M

Lark develops AI agents that automate manual workflows for wholesale distributors, integrating with their existing ERP systems and learning from each distributor's historical data and team decisions.

Advanced ManufacturingAI & Machine LearningSan Francisco, US

Jason Wang(Founder/CEO)in Michael Wang(Co-Founder)in

Co-investorsY Combinator Franklin Templeton King River Capital

Lumerislumeris.com in 𝕏Apr 2024 · $100M

Lumeris uses AI combined with human-centered design to address the U.S. primary care shortage, co-creating an AI tool called Tom with physicians and patients to deliver Primary Care as a Service.

AI & Machine LearningDigital HealthHealthtechSt. Louis, US

W. Michael Long(Chairman & Chief Executive Officer, Lumeris Group Holdings Corporation)

Co-investorsBlue Venture Funds Havencrest Capital Management Kleiner Perkins BlueCross BlueShield Venture Partners Sandbox Industries

Lumos Pharmalumos-pharma.com in 𝕏Apr 2016

Lumos Pharma is a clinical-stage biopharmaceutical company developing therapies for rare diseases, with a lead candidate targeting Pediatric Growth Hormone Deficiency.

BiotechHealthtechAustin, US

Richard John Hawkins(Executive Officer, Director)John C. McKew(President and Chief Scientific Officer)in Pisit "Duke" Pitukcheewanont(Chief Medical Officer)in Lori Lawley(Chief Financial Officer)in Brad Powers(Chief Compliance Officer and General Counsel)in Campbell Murray(Executive Chairman)in

Co-investorsNew Enterprise Associates (NEA)Clarus Ventures Sante Health Ventures Sante Ventures Wellcome Trust

Metacrinemetacrine.comJun 2018 · $65M

San Diego clinical-stage biopharma developing non-bile acid FXR agonists for liver and gastrointestinal diseases.

BiotechSan Diego, US

Ronald Evans(Director)Trisha Millican(Executive Officer)Ken Song(Executive Officer, Director)

Board Kristina Burow(Director)in Richard Heyman(Director)in Amir Nashat(Director)in

Co-investorsage1 EcoR1 Capital LAV LifeSci Venture Partners Lilly Asia Ventures New Enterprise Associates (NEA)+8 more

myLaurelmylaurelhealth.com inSeries B · Jun 2025 · $12M

myLaurel provides in-home medical care aimed at improving access for high-risk patients, working with clinicians and care teams.

Digital HealthHealthtech

Co-investorsBeresford Ventures City Light Frist Cressey Ventures GV (Google Ventures)SteelSky Ventures WEEKEND

Nema Health inSeries A · Nov 2024 · $15M

HealthtechBranford, US

Sofia Noori(Executive Officer, Director)Mariam Malik(Executive Officer)in

Board Laura Veroneau(Director)Adrienne Rosenthal(Director)

Co-investors.406 Ventures Optum Ventures

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Aprecia Pharmaceuticals Conventus Orthopaedics Humanity Health, Inc.Iowa Approach Perfect Health Springtide Child DevelopmentAltus PharmaceuticalsAveXisBitterroot BioBlade Therapeutics Chondrial TherapeuticsCOTA HealthcareCovagen AGEpion HealthHana BiosciencesLiquid WireMMINeomorphPairwise PlantsPerceive BiotherapeuticsPerceive PharmaPhoenix Nuclear Labs PQ Bypass Ray Therapeutics Ready Responders Relation Therapeutics Spark TherapeuticsV-WaveVibliome TherapeuticsVicinitas TherapeuticsVital AccessZed Industries剂泰科技 (METiS TechBio)

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Exits · 17

15 IPOs · 2 acquisitions · showing 14

BiomxNYSE: PHGEBlack Diamond Therapeutics, IncNASDAQ: BDTXCabaletta BioNASDAQ: CABAEdgewise TherapeuticsNASDAQ: EWTXEditas MedicineNASDAQ: EDITFoghorn TherapeuticsNASDAQ: FHTXGenedxNASDAQ: WGSKiniksaNASDAQ: KNSAMirum PharmaceuticalsNASDAQ: MIRMPacific Biosciences of CaliforniaNASDAQ: PACBScynexisNASDAQ: SCYXXilio TherapeuticsNASDAQ: XLOCovagen AGacq. by Johnson & JohnsonTrivascularacq. by Endologix

Portfolio news

latest coverage across their companies

AI voice startup ElevenLabs doubles valuation to $22B

ElevenLabs · techcrunch.com · Sep 30, 2026

Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference

Black Diamond Therapeutics, Inc · finance.yahoo.com · Sep 2, 2026

Elion Therapeutics Announces Initiation of Turletricin (EL219) Phase 2 Study in Invasive Mould Infection - BioSpace

Elion Therapeutics · biospace.com · Apr 16, 2026

Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026

Foghorn Therapeutics · globenewswire.com · Jan 10, 2026

Lark: Stripe without the workarounds

Lark · ycombinator.com · Dec 4, 2025

Excelsior Sciences Raises $95M in Funding

Excelsior Sciences · finsmes.com · Dec 4, 2025

Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections

Scynexis · finance.yahoo.com · Nov 17, 2025

Axon Therapies Raises $32M in Oversubscribed Series A to Transform Heart Failure Treatment

Axon Therapies · prnewswire.com · Sep 25, 2025

Fund performance · per public LP disclosures

as of Jun 2024

Fund	Vintage	Committed	Net IRR	TVPI	DPI
Deerfield Private Design Fund IVLPs: Florida State Board of Administration, Robert Wood Johnson Foundation	2007	—	7.9%	1.45x	0.11x

Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).

IPO stake values · per SEC filings · 7

Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.

Company	Owned	IPO price	At IPO	Stake value
Edgewise Therapeutics	7.0%	$16.00	Mar 2021	$52.9M
Pacific Biosciences of California	3.9%	$16.00	Oct 2010	$32.4M
Editas Medicine	4.8%	$16.00	Feb 2016	$27.4M
Xilio Therapeutics	5.7%	$16.00	Oct 2021	$24.2M
Kiniksa	6.7%	$18.26	Feb 2019	$22.4M
Cabaletta Bio	3.9%	$11.00	Oct 2019	$10.2M
Scynexis	3.8%	$7.70	Apr 2015	$3.9M

Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).

Public market activity · per SEC filings

what is this? ⓘ

59 insider ownership filings (Forms 3/4/5)

From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.

Frequently asked questions

How many investments has Deerfield Management Company made?: Deerfield Management Company has 112 tracked investments, 17 of which have exited, including 11 dated in the last 24 months.
What stage does Deerfield Management Company invest at?: Deerfield Management Company invests at the Growth, Late Stage stages.
What sectors does Deerfield Management Company focus on?: Deerfield Management Company focuses on AI & Machine Learning, Biotech, Digital Health, Healthtech, Medical Devices.
Where is Deerfield Management Company located?: Deerfield Management Company is headquartered in New York, US.
Does Deerfield Management Company lead rounds?: Deerfield Management Company has led 13 of the 24 rounds where its role is on record.
Who does Deerfield Management Company co-invest with?: Deerfield Management Company most often shares deals with HongShan Capital Group, Longwood Fund, Star51 Capital, among 3 tracked co-investors.

Images

Co-investors · 38

GV (Google Ventures)

GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.

Both backed · 9

Editas Medicine Element Science Encodia myLaurel Perceive Biotherapeutics Ready RespondersBitterroot BioPerceive PharmaVicinitas Therapeutics

$250K – $50M

New Enterprise Associates (NEA)

New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.

Both backed · 7

Black Diamond Therapeutics, Inc Mirum Pharmaceuticals Annexon ElevenLabs Lumos Pharma Metacrine Trivascular

$200K – $40M

ARCH Venture Partners

ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.

Both backed · 6

Encodia Homology Medicines Jaguar Gene Therapy Metacrine Syros Pharmaceuticals, Inc.Bitterroot Bio

$50K – $250M

OrbiMed

OrbiMed is a healthcare-focused investment firm providing tailored financing solutions and global resources to build world-class healthcare companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.

Both backed · 6

Biomx Edgewise Therapeutics Acutus Medical Adela Audentes Therapeutics Practice Fusion

$1M – $75M

Foresite Capital

Foresite Capital is a healthcare-focused investment firm backing companies at the intersection of technology and biotechnology to personalize healthcare and accelerate medical innovation.

Both backed · 5

Edgewise Therapeutics Scynexis AveXis Generation Bio Pleno Inc.

Optum Ventures

Optum Ventures is a healthcare-focused venture capital firm affiliated with UnitedHealth Group's Optum platform, investing in emerging healthcare and digital health companies across the US and globally.

Both backed · 5

Cortica Nema Health Somatus Springtide Child Development Vanta

Andreessen Horowitz

Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.

Both backed · 4

ElevenLabs Eligible HumanityVicinitas Therapeutics

$500K – $50M

OUP (Osage University Partners)

OUP (Osage University Partners) is a venture firm that invests in science-driven startups commercializing deep technology innovations emerging from university and breakthrough research.

Both backed · 4

Blade Therapeutics Dracen Pharmaceuticals Homology Medicines Ribon Therapeutics

$1M – $20M

US Venture Partners

US Venture Partners (USVP) is an early-stage venture capital firm investing in information technology and healthcare companies, with four decades of investing experience.

Both backed · 3

Edgewise Therapeutics Neochord SentreHeart

$500K – $10M

5AM Ventures

5AM Ventures is a life science venture capital firm founded in 2002 that funds and builds next-generation life sciences companies, focusing on biopharmaceuticals, drug delivery technologies, and life science instruments.

Both backed · 3

Cabaletta Bio Audentes Therapeutics Homology Medicines

$100K – $4M

MPM BioImpact

MPM BioImpact combines 30+ years of biotech venture capital expertise with impact investing and public market experience, managing early-stage venture funds, private/public impact funds, and a public equities fund focused on transforming patient outcomes.

Both backed · 3

Blade Therapeutics Frontier Medicines Oncorus

$1M – $15M

Vivo Capital

Vivo Capital is a global healthcare-focused investment firm operating a multi-strategy platform spanning venture capital, private equity, and public equity. It aims to expand healthcare access and drive innovation through its 'Ecosystem Strategy.'

Both backed · 3

Homology Medicines Metacrine SentreHeart

$10M – $50M

▶26 more co-investors

Andera Partners Franklin Templeton SteelSky Ventures Sequoia Capital DCVC (Data Collective)Canaan Partners Obvious Ventures Flare Capital Partners City Light Novartis Venture Fund RiverVest Venture Partners APERTURE Venture Partners Tiger Global Management Oak HC/FT Vast Ventures S32 Northpond Ventures Frazier Healthcare Partners Roche Venture Fund Merck Global Health Innovation Fund King River Capital Bain Capital Ventures C2 Investments Paradigm Haun Ventures Domain Associates

Firms observed investing alongside Deerfield Management Company, from public investor directories. Shared companies are the overlap with Deerfield Management Company's recorded portfolio.

Similar investors

Eight Roads Ventures

Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.

$5M – $30M

Sanofi Ventures

Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies aligned with Sanofi's mission of advancing human health.

$5M

SPRINGROCK VENTURES

SpringRock Ventures is a Seattle-based venture firm investing in the convergence of healthcare and information technology, backing companies across digital health, medical devices, oral health, healthcare SaaS and related innovation.

$2M – $5M

Bayern Kapital

Bayern Kapital is a public venture capital and growth investor backing innovative Bavarian high-tech, deep tech and life sciences start-ups and scale-ups, acting as an anchor investor across multiple funding rounds.

$275K – $55M

iGan Partners

iGan Partners is a Toronto-based venture capital firm that backs founders commercializing and scaling healthcare technology innovations, offering capital, active support, and access to industry partners and co-investors.

$365K – $2.2M

Featured in lists

Website & social

deerfield.com

signal ↗crunchbase ↗

As published on the firm's website.

Contact

345 Park Avenue South
New York, NY 10010
United States

FoxScore

Combines investment activity, responsiveness, founder feedback, closing rate and follow-through reported by founders on Fox. Sign up to see it.

Your history

Deerfield Management Company isn't in your CRM yet.

+ Add to CRM

Track outreach, deck opens, and next steps across your whole raise.

✨ Smart outreach

✨ Best warm path

Funds

DEERFIELD PARTNERS, L.P.Jul 2026 · 192 LPs$9BAUM

DEERFIELD HEALTHCARE INNOVATIONS FUND, L.P.Jul 2026 · 126 LPs$1.8BAUM

DEERFIELD PRIVATE DESIGN FUND III, L.P.Jul 2026 · 153 LPs$1.5BAUM

DEERFIELD PRIVATE DESIGN FUND V, L.P.Jul 2026 · 95 LPs$1.3BAUM

DEERFIELD HEALTHCARE INNOVATIONS FUND II, L.P.Jul 2026 · 95 LPs$774.9MAUM

DEERFIELD HEALTHCARE INNOVATIONS FUND III, L.P.Jul 2026 · 56 LPs$414.7MAUM

DEERFIELD HEALTHCARE INNOVATIONS FUND III-A, L.P.Jul 2026 · 41 LPs$169.6MAUM

DEERFIELD STRATEGIC GROWTH FUND, L.P.Jul 2026 · 2 LPs$121.9MAUM

DEERFIELD PRIVATE DESIGN FUND II, L.P.Jul 2026 · 62 LPs$100.7MAUM

DEERFIELD PRIVATE DESIGN INTERNATIONAL II, L.P.Jul 2026 · 42 LPs$80.3MAUM

DEERFIELD PDI FINANCING II, L.P.Jul 2026 · 42 LPs$35.3MAUM

+1 more funds

Source: SEC Form ADV Schedule D and EDGAR Form D filings. AUM is gross asset value as reported by the adviser.